



## NEWS RELEASE

### Contact:

Milena Christankova  
DiabetOmics Public Relations  
404.395.8097  
[mchristankova@diabetomics.com](mailto:mchristankova@diabetomics.com)

### **DiabetOmics Licenses Technology to Advance Testing for Preeclampsia, Gestational Diabetes**

#### ***DiabetOmics Test to be Integrated into BD Veritor™ Point-of-Care Diagnostic Platform***

**PORTLAND, OR, Feb. 1, 2016** – Diabetomics, Inc., a privately-held global medical diagnostics company, today announced it has entered into a licensing and distribution agreement for a clinical test with BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company. The newly developed pregnancy-specific metabolic test helps provide early identification for preeclampsia and gestational diabetes.

Preeclampsia is the second-leading cause of maternal death and gestational diabetes is the most common prenatal complication, affecting up to 16 percent of pregnancies worldwide. DiabetOmics has identified glycosylated fibronectin (GlyFn) as a biological marker for the early identification of both conditions. BD plans to create simple, affordable assays using GlyFn on its BD Veritor™ point-of-care diagnostic platform. BD also plans to distribute DiabetOmics' own point-of-care test and reader, currently under development, in select international markets.

“DiabetOmics is pleased to enter into this agreement with BD. We believe BD has the ability to establish global access to these innovative tests for women around the world. Our company's mission is to advance the health and wellbeing of pregnant women at risk for preeclampsia and diabetes through the application of clinical insight and advanced technology aimed at improving the diagnosis and monitoring of these conditions and their resulting complications”, says Sri Nagalla, CEO of DiabetOmics.

“BD has a long history of developing innovations to address unmet health needs and making these accessible throughout the world,” said Gary Cohen, Executive Vice President and President of Global Health for BD. “We are focusing on maternal and newborn mortality and morbidity because these are areas of significant unmet need, particularly in resource-poor settings. Having an

affordable, accessible and easy-to-use testing platform for the identification of both preeclampsia and gestational diabetes will be a large step forward to improve maternal health around the world.”

### **About DiabetOmics**

**DiabetOmics, Inc.** is a global medical diagnostics company pioneering innovative, non-invasive point-of-care tests for the detection and monitoring of diabetes and pregnancy complications. The company's mission is to advance the health and wellbeing of patients through simple, cost-effective, and easily accessible care. DiabetOmics' goal is to develop and provide point-of-care testing capabilities that are especially useful in alleviating the substantial economic and public health burden of diabetes and certain pregnancy complications in underserved, low-resource environments, particularly for at-risk populations in low/middle-income countries. For more information, please visit [www.diabetomics.com](http://www.diabetomics.com).

# # #